Printer Friendly

XOMA REPORTS 1992 SECOND QUARTER FINANCIAL RESULTS

 XOMA REPORTS 1992 SECOND QUARTER FINANCIAL RESULTS
 BERKELEY, Calif., July 30 /PRNewswire/ -- XOMA Corp.


(NASDAQ-NMS: XOMA) today reported its financial results for the 1992 second quarter.
 For the quarter ended June 30, 1992, XOMA had revenues of $1.9 million and a net loss of $11.5 million ($0.54 per share), including a one-time, non-cash charge of $3.3 million related to the settlement of securities litigation. Without the charge, the company's second quarter 1992 loss would have been $8.3 million, or $0.39 per share. In the comparable 1991 period, XOMA had revenues of $4.9 million and recorded a net loss of $8.1 million ($0.41 per share). The decline in revenues in the 1992 second quarter was due primarily to lower research and development fees from and product sales to Pfizer Inc., the company's marketing partner for its E5 anti-endotoxin monoclonal antibody product.
 At June 30, 1992, XOMA had total assets of $135.3 million including cash and short-term investments of $104.1 million, long-term debt of $1.3 million, and stockholders' equity of $115.9 million.
 XOMA is a leading biotechnology company in the development of pharmaceutical products based on monoclonal antibody and recombinant DNA technologies.
 XOMA CORP.
 Balance Sheet Data
 (in thousands)
 June 30, Dec. 31,
 1992 1991
 Current assets $118,745 $139,495
 Total assets 135,262 154,289
 Long-term debt 1,279 1,503
 Stockholders' equity 115,890 134,456
 Statement of Operations Data
 (in thousands except per share data)
 Three Months Ended Six Months Ended
 June 30, June 30,
 1992 1991 1992 1991
 Total revenues $1,864 $4,927 $3,810 $10,053
 Total operating
 costs and expenses 11,400 14,755 22,923 26,850
 Other income
 (expense) 1,276 1,735 3,161 2,080
 Litigation
 settlement (3,250) 0 (3,250) 0
 Net loss (11,510) (8,093) (19,202) (14,717)
 Net loss per share (0.54)(A) (0.41) (0.90)(B) (0.85)
 Weighted average
 common shares
 outstanding 21,445 19,838 21,437 17,353
 (A) $(0.39) pe share, without $3,250 non-cash charge for litigation settlement.
 (B) $(0.75) per share, without $3,250 non-cash charge for litigation settlement.
 Shares outstanding at June 30, 1992: 21,448,783
 -0- 7/30/92
 /CONTACT: Carol D. DeGuzman of XOMA, 510-644-1170/
 (XOMA) CO: XOMA ST: California IN: MTC SU: ERN


RM-MM -- SF004 -- 5215 07/30/92 15:19 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 30, 1992
Words:407
Previous Article:QUAKER STATE REPORTS EARNINGS, DECLARES DIVIDEND
Next Article:KENAN TRANSPORT COMPANY REPORTS SECOND QUARTER RESULTS
Topics:


Related Articles
XOMA ANNOUNCES YEAR-END FINANCIAL RESULTS
XOMA COMMENTS ON FDA REVIEW OF E5
XOMA ANNOUNCES NEW STRATEGIC FOCUS AND RESTRUCTURING
XOMA REPORTS SECOND QUARTER FINANCIAL RESULTS
XOMA REPORTS THIRD QUARTER FINANCIAL RESULTS
XOMA REPORTS FOURTH QUARTER, YEAR-END FINANCIAL RESULTS
XOMA REPORTS 1994 FIRST QUARTER FINANCIAL RESULTS
XOMA REPORTS 1994 THIRD QUARTER FINANCIAL RESULTS
MorphoSys Announces Share Issuance for XOMA License.
XOMA to Announce Third Quarter 2008 Financial Results and Host Conference Call on November 10.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters